Reason for CPXcitement in AML

Joshua F. Zeidner; Judith E. Karp

doi:10.1182/blood-2014-04-568725

Reason for CPXcitement in AML

Joshua F. Zeidner, Judith E. Karp

School of Medicine

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

In this issue of Blood, Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 713 in older patients with acute myeloid leukemia (AML).

Original language	English (US)
Pages (from-to)	3211-3212
Number of pages	2
Journal	Blood
Volume	123
Issue number	21
DOIs	https://doi.org/10.1182/blood-2014-04-568725
State	Published - May 22 2014

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2014-04-568725

Cite this

@article{3499c67d841947c99966f1e0210d3056,

title = "Reason for CPXcitement in AML",

abstract = "In this issue of Blood, Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 713 in older patients with acute myeloid leukemia (AML).",

author = "Zeidner, {Joshua F.} and Karp, {Judith E.}",

year = "2014",

month = may,

day = "22",

doi = "10.1182/blood-2014-04-568725",

language = "English (US)",

volume = "123",

pages = "3211--3212",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "21",

}

TY - JOUR

T1 - Reason for CPXcitement in AML

AU - Zeidner, Joshua F.

AU - Karp, Judith E.

PY - 2014/5/22

Y1 - 2014/5/22

N2 - In this issue of Blood, Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 713 in older patients with acute myeloid leukemia (AML).

AB - In this issue of Blood, Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 713 in older patients with acute myeloid leukemia (AML).

UR - http://www.scopus.com/inward/record.url?scp=84901476343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901476343&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-04-568725

DO - 10.1182/blood-2014-04-568725

M3 - Review article

C2 - 24855187

AN - SCOPUS:84901476343

SN - 0006-4971

VL - 123

SP - 3211

EP - 3212

JO - Blood

JF - Blood

IS - 21

ER -

Reason for CPXcitement in AML

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this